I am the Chief of the Hematologic Malignancy, Bone Marrow Transplantation and Cellular Therapy Program at Beth Israel Deaconess Medical Center. I lead a large research program in personalized immune based therapies for cancer including cancer vaccines and CAR T cells. We have developed a patient specific cancer vaccine. In clinical trials, vaccination was associated with disease regression and reduction in risk of relapse. We are now leading several national vaccine trials.
I think it is critical to have a good understanding of the disease and the treatment options in an open and transparent way. Developing a close connection with your caregiver, and being able to explore these options together in a way that respects the individuality of each patient, and their situation is vital.
We have the great privilege to care for patients at a difficult and uncertain time and offer support and help. Their courage inspires our whole team to work tirelessly to offer the highest level of care and seek better therapies.
We provide state of the art therapy including cutting edge research and personalized immune based therapies for patients facing blood cancers. I lead an integrated multidisciplinary team of clinicians and researchers that work together to emphatically deliver care with a focus on the unique qualities and dignity of each patient. We are proud to offer a large panel of clinical trials including personalized cancer vaccines and CAR T cells
All major insurance, Medicare, and Medicaid
Keywords: Immunotherapy, hematological malignancies, CAR T, vaccine